Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

SUMMARY: BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This is a pros...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Higashihara, Eiji, Torres, Vicente E., Chapman, Arlene B., Grantham, Jared J., Bae, Kyongtae, Watnick, Terry J., Horie, Shigeo, Nutahara, Kikuo, Ouyang, John, Krasa, Holly B., Czerwiec, Frank S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Nephrology 2011
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359559/
https://ncbi.nlm.nih.gov/pubmed/21903984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.03530411
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak